Introduction
Cutaneous vasculitis refers to a miscellaneous group of conditions in which one of the primary histological defects is inflammation of the skin blood vessels; fibrinoid necrosis and vasular occlusion may follow. The clinical picture depends on the site, size, and number of vessels affected, and so one may see any combination of purpura, papules, nodules, necrosis, and even ulceration. The pathogenesis, however, is unknown but recent investigations (Cochrane, 1968; Katz et al., 1968; Cream, 1972) (Isacson et al., 1970) and appear at the moment to be of little help in the understanding of the development of the vasculitic lesion. Studies of fibrinolysis, however, have been more detailed and interesting. Cunliffe (1968) reported three patients who had a persistently reduced fibrinolytic activity as shown by a prolonged euglobulin lysis time, and which retumed to normal in two cases as the vasculitis spontaneously healed.
Cunliffe and Menon (1971) further investigated 52 patients with a vasculitis predominantly affecting the skin. Of these, 32 patients had a significantly reduced plasma fibrinolytic activity. The same authors reported in an uncontrolled study that in nine out of 10 patients who received oral fibrinolytic therapy with phenformin hydrochloride and ethyloestrenol clinical improvement occurred over a period of 6-36 weeks. Isacson et al., (1970) reported a decreased blood fibrinolytic activity in four of 11 patients with chronic vasculitic lesions of the lower legs. Parish (1972) also reported eight patients six of whom had a decreased blood fibrinolytic activity. In contrast to these findings, however, Kurban and Ryan (1969) and Vaithianathan and Takats (1968) were unable to detect a reduced fibrinolytic activity in patients with a vasculitis.
Published data on the treatment of cutaneous vasculitis with fibrinolytic therapy from other centres are not available. Clearly, therefore, the field was set for a more detailed, preferably double-blind study of oral fibrinolytic therapy in patients with chronic vasculitis. At the same time it appeared prudent to measure fibrinogen-fibrin-related antigen (F.R.-antigen) in these patients with a demonstrable disorder of their fibrinolytic mechanisms.
Patients and Methods Each of the 13 patients who entered the trial had a vasculitis of at least six months' duration and the clinical details are given in table I. Therapy consisted of either phenformin (slow release) 50 mg twice a day and ethyloestrenol 2 mg four times a day or phenformin (slow release) 50 mg twice a day and stanozolol 5 mg twice a day or matched placebo tablets.
The treatment was changed three monthly by the pharmacAst without the knowledge of the patient or investigator.
Before treatment and at monthly intervals the clinical picture was assesssed and fibrinolytic activity and F.R.-antigen level estimated.
The clinical assessment was graded according to the distribution, number, frequency, severity, and persistence of the lesions. Grade 0-6 indicated an increasing order of severity for each patient before and during the trial.
Fibrinolytic activity of the plasma was assessed by the euglobulin lysis time, which was estimated by the method of von Kaulla (1963) as modified by Menon (1967) using an automatic euglobulin clot-lysis recorder (Carmanen Instruments Ltd.). The F.R.-antigen titre was measured by the tanned red cell haemagglutination inhibition technique of Merskey et al., (1966) .
Before treatment diabetes mellitus was excluded and urea and liver function tests were checked on each visit.
Results
Altogether, 12 patients completed the full nine months of the trial; of these, seven did well clinically when treated with either phenformin and ethyloestrenol or phenformin and stanozolol whereas the other five failed to show any significant improvement whatsoever (table I) . One patient (case 13) was withdrawn from the trial at the fourth month. This patient, with a chronic panniculitis unresponsive to steroids, improved greatly during the first three months when on phenformin and stanozolol. When therapy was changed to the placebo extensive recurrence of the panniculitis occurred and the treatment code had to be broken. The patient has since been treated satisfactorily with phenformin and stanozolol or phenformin and ethyloestrenol. On two occasions his therapy was discontinued and this was associated with a relapse of his panniculitis and a decrease in his blood fibrinolytic activity to 320 minutes. In one of these relapses a biopsy specimen of normal leg skin was taken for tissue fibrinolytic studies (Dodman et al., 1973) and the biopsy site developed into an extensive panniculitic lesion. This was in contrast to a biopsy specimen taken while on treatment, when the biopsy site healed well.
Of the other 12 subjects there was no particular diagnostic group of patients who appeared to respond better than others and neither drug combination was superior to the other. The 83 fibrinolytic activity before and during the trial in one patient (case 1) who clinically had a good response with almost complete resolution of the rash during active treatment is shown in fig. 1 . Apart from one result, the fibrinolytic therapy maintained an improved fibrinolytic state during the phase of clinical remission. The patient was under observation for a further 54 weeks after completing the trial ( fig. 1) The fibrinolytic activity of one of the five patients who showed no clinical improvement is illustrated in fig. 2 . Although there was no clinical improvement there was an improved blood fibrinolytic activity with active therapy.
The overall fibrinolytic response to drug therapy is given in table II. With the placebo treatment there was no increase or decrease in the fibrinolytic activity but on active therapy the fibrinolytic activity was significantly improved. Phenformin and stanozolol increased the fibrinolytic activity more than phenformin and ethylestrenol when comparison is made of the 12 subjects who completed the nine months' trial but the difference was not significant (P 0-2). However, a paired t test comparing the successfully and unsuccessfully treated groups showed that the fibrinolytic activity during the pretreatment and placebo periods was significantly impaired (P <005) in those patients who had a satisfactory clinical response to therapy. There was no increase in F.R.-antigen either before or during treatment (table III) . (Cunliffe, 1968; Isacson et al., 1970; Cunliffe and Menon, 1971; Parish, 1972) . Gallimore et al. (1972) have shown in experimental studies that fibrin deposition within the circulation is necessary before increased F.R.-antigen levels are produced by a vigorous fibrinolytic state. Although fibrin deposition is a feature of certain types of vasculitis (Isacson et al., 1970) no difference in the F.R.-antigen levels between treated and control groups could be detected. This finding is in keeping with the report of Gormsen and Vad (1970) 
